Second-Generation Antipsychotics and Tardive Syndromes in Affective Illness: A Public Health Problem With Neuropsychiatric Consequences.

• Autores: Frederick M. Jacobsen
• Localización: American journal of public health, ISSN 0090-0036, Vol. 105, Nº. 2, 2015, págs. 10-16
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Food and Drug Administration– approved information and public advertisements belie neurodegenerative risks for second-generation antipsychotics in affective illness. Package inserts label tardive syndromes “potentially reversible” while uniformly omitting patient counseling for long-term neurodegenerative side effects. I found that only 2 of 78 outpatients exposed to second-generation antipsychotics reported awareness of tardive syndromes. Updated literature challenges safety advantages of atypical versus typical antipsychotics. Physician and patient information regarding tardive syndromes from second-generation antipsychotics approved for affective illness is inadequate. [ABSTRACT FROM AUTHOR]